NASDAQ •
Healthcare •
Diagnostics & Research •
Quote as of 09/04/2026 16:00
Company Profile
IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10.8 mln
Float0.59 mln
Earnings Date11/13/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.77
Likely manipulated
Relative Strength
100
/ 100
Top performer
Debt / Equity
0.38
Low leverage
Pre-Tax Margin
-260%
Severely loss-making
ROE
-354
Deeply negative
Business Description
bioAffinity Technologies is a San Antonio-based company focused on catching lung cancer early, before it becomes harder to treat. Their main product, CyPath Lung, examines a patient's mucus sample to identify cells that suggest the presence of a lung tumor, all without the need for invasive procedures. Founded in 2014, the company combines laboratory services with ongoing research to improve how lung diseases are detected and understood.
